Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nimotuzumab + toripalimab + chemotherapy for early-stage laryngeal/hypopharyngeal squamous cell carcinoma
ChiCTR2600124919Phase 2Recruiting
- Sponsor
- Shandong Second People's Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and toripalimab in laryngeal squamous cell carcinoma (LSCC), squamous cell carcinoma of the hypopharynx and head and neck squamous cell carcinoma (HNSCC), sponsored by Shandong Second People's Hospital. Primary endpoint: Objective Response Rate (ORR). Started May 2026; status: recruiting.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600124919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124919.